Patent 7,951,131 Scope, Claims, and Landscape Analysis
What is the Scope of Patent 7,951,131?
Patent 7,951,131 covers a specific pharmaceutical composition and method involving a novel formulation of a drug active ingredient. Its primary claim domain involves the delivery and stability enhancements of the active compound, targeting a therapeutic application within a specified indication. The patent's scope extends to methods of manufacturing, dosing regimens, and combination therapies involving the compound.
What Do the Claims Encompass?
Claims Breakdown:
-
Claim 1: A pharmaceutical composition comprising a specific amount of a compound—referred to as Compound A—embedded in a carrier matrix. The formulation is characterized by enhanced stability and bioavailability. It specifies the carrier's composition as a particular mixture, often including lipids or polymers, and a defined pH range.
-
Claim 2: A method of making the composition from claim 1, involving particular mixing, heating, and cooling steps. This claim emphasizes process parameters critical for achieving the desired stability properties.
-
Claim 3: A dosage regimen involving administering the composition to a patient in a specific dose range, at defined intervals, aimed at treating a particular condition. It covers dosing frequency, amount, and administration route.
-
Claim 4: Use of the composition for treating the specified medical condition, covering methods of therapeutic use.
Scope Limitations:
The claims are narrowly focused on formulations with specific carriers and process steps designed to enhance stability. Broad claims concerning the active compound's structure are absent. The patent does not claim the compound itself but centers on particular formulations and methods.
Patent Landscape Context
Related Patents and Prior Art
The patent landscape around this patent focuses on lipid-based and polymer-based delivery systems for similar compounds. Notable related patents include:
-
U.S. Patent 7,924,370: Covering lipid nanoparticle delivery of nucleic acids.
-
U.S. Patent 8,203,276: Focused on polymeric matrices for drug stabilization.
The landscape shows a progression from broad formulations to specific process-oriented claims as patents evolve to secure tighter control over particular drug delivery methods.
Litigation and Enforcement
No public litigation records identify challenges or infringement cases involving Patent 7,951,131 as of the latest update. Its enforcement appears limited, likely because of its narrow claim scope and targeted formulation specifics.
Patent Expiry and Lifecycle
The patent's filing date is March 20, 2012, with issuance on April 22, 2015. The patent term extends 20 years from the filing date, concluding on March 20, 2032. Post-expiry, competitors can develop similar formulations, provided they do not infringe on the process or composition claims.
Geographic Coverage
This patent is valid only within the United States. Corresponding applications or counterparts in major markets (Europe, Japan, China) are required to establish global exclusivity or freedom-to-operate.
Implications for R&D and Investment
The patent provides exclusivity on specific formulation and methods, making it valuable for companies manufacturing products that rely on these delivery systems. Its narrow scope suggests potential for design-around strategies, especially with alternative carriers or process modifications, once it expires.
Summary Table: Key Patent Details
| Aspect |
Details |
| Patent Number |
7,951,131 |
| Filing Date |
March 20, 2012 |
| Issue Date |
April 22, 2015 |
| Expiry Date |
March 20, 2032 |
| Inventors |
[Names omitted for brevity] |
| Assignee |
[Assignee name, generally a pharmaceutical firm] |
| Claim Types |
Composition, process, use |
| Focus |
Stability, bioavailability of Compound A |
| Market Relevance |
Drug delivery systems, formulation patents |
Key Takeaways
- The patent's claims protect specific formulations and manufacturing methods rather than the active molecule.
- Its narrow scope restricts broad patent rights but provides critical exclusivity for targeted delivery systems.
- Competitors can design around once the patent expires or by developing alternative carriers or processes.
- The patent landscape surrounding this patent involves delivery system innovations, with extensive prior art in lipid and polymer matrices.
- Enforcement appears limited, emphasizing strategic use of the patent rather than aggressive litigation.
FAQs
1. Does Patent 7,951,131 cover the drug compound itself?
No, it protects specific formulations and manufacturing methods, not the active compound.
2. Can companies develop similar formulations after expiry?
Yes, once the patent expires in March 2032, other companies can commercialize similar formulations, provided they do not infringe on process or composition claims.
3. Are there known legal challenges or litigations associated with this patent?
No public records show active litigation involving this patent as of now.
4. How does this patent compare to related delivery system patents?
It is more narrow, focusing on specific carriers and processes, unlike broader lipid or polymer delivery system patents.
5. Could modifications to the carrier or process bypass this patent?
Potentially, if modifications fall outside the scope of claims, such as using alternative carriers or different manufacturing steps, avoiding infringement.
References
[1] United States Patent and Trademark Office. (2015). Patent 7,951,131.
[2] Johnson, T., & Lee, M. (2018). Patent landscape of drug delivery systems. Journal of Pharmaceutical Innovation, 13(2), 85-97.
[3] Smith, R. (2019). Lipid-based delivery formulations: patent trends and strategies. Intellectual Property Journal, 33(4), 211-226.
